Available online www.jsaer.com

***Journal of Scientific and Engineering Research*, 2020, 7(1):278-281**

Research Article

ISSN: 2394-2630
CODEN(USA): JSERBR

Optimizing Biological Age: A Key to Extending Healthspan and Lifespan

Durga Prasad Amballa

Hyderabad, India
Email id: adprasad.amballa@gmail.com

Abstract Chronological age is an imperfect measure of an individual's health status and longevity potential. In contrast, biological age, which reflects the functional status of an organism, is a more accurate predictor of morbidity and mortality risk. Identifying biomarkers of biological age and developing interventions to maintain or improve these markers could lead to extended healthspan and lifespan. This paper reviews the concept of biological age, its measurement through key biomarkers, and potential strategies for optimization. We discuss the role of epigenetic, telomeric, inflammatory, metabolic, and functional markers in assessing biological age and their potential as targets for interventions. Lifestyle factors, such as diet, exercise, and stress management, as well as pharmacological and regenerative therapies, are explored as strategies to modulate biological age. We also highlight the challenges and future directions in the field of biological aging, emphasizing the need for standardized biomarker panels, personalized interventions, and longitudinal studies to validate the efficacy of biological age optimization in promoting healthy longevity.

Keywords biological age, chronological age, healthspan, lifespan, aging biomarkers, lifestyle interventions, pharmacological therapies, regenerative medicine

Introduction

Aging is a complex, multifactorial process characterized by progressive functional decline and increased susceptibility to disease and death [1]. While chronological age (CA) is widely used as a measure of an individual's aging process, it fails to capture the heterogeneity in health status and longevity among individuals of the same age [2]. Biological age (BA), on the other hand, reflects the functional capacity and physiological status of an organism, providing a more accurate assessment of an individual's health and mortality risk [3].

The concept of BA has gained significant attention in recent years, as researchers seek to identify reliable biomarkers that can predict an individual's rate of aging and potential for healthy longevity [4]. By understanding the mechanisms underlying biological aging and developing interventions to optimize BA, we may be able to extend healthspan, the period of life spent in good health, and ultimately prolong lifespan [5].



Fig. 1: Schematic representation of the relationship between chronological age and biological age, highlighting the potential for individuals to have a higher or lower biological age relative to their chronological age

Problem Statement

The current approach to assessing an individual's health and longevity relies heavily on CA, which fails to account for the variability in the aging process among individuals. This leads to several problems:

[1]. Inaccurate risk assessment: CA does not accurately reflect an individual's risk of developing age-related diseases or experiencing functional decline [6]. This can result in under- or over-estimation of health risks, leading to inappropriate medical interventions or missed opportunities for prevention.

[2]. Lack of personalized interventions: Health recommendations and interventions based on CA may not be optimal for individuals with a higher or lower BA [7]. This one-size-fits-all approach fails to consider the unique biological profile of each individual, potentially limiting the effectiveness of interventions.

[3]. Limited understanding of aging mechanisms: Focusing solely on CA hinders the understanding of the complex biological processes that contribute to aging and the development of targeted interventions to modulate these processes [8].

To address these problems, there is a need for a more comprehensive approach to assess an individual's biological age and develop personalized interventions to optimize healthspan and lifespan.

Solution

The solution to the problems associated with relying on CA lies in the identification and measurement of reliable biomarkers of BA and the development of targeted interventions to modulate these markers. This solution involves several key components:

[1]. Identification of BA biomarkers: Researchers have identified several promising biomarkers of BA, including epigenetic clocks, telomere length, inflammatory markers, metabolic profiles, and functional measures [9]. These biomarkers provide a more accurate assessment of an individual's biological age and can be used to track the effectiveness of interventions.

[2]. Development of standardized biomarker panels: To facilitate the widespread use of BA assessment in clinical settings, there is a need for standardized biomarker panels that can be easily measured and interpreted [10]. These panels should include a combination of biomarkers that capture different aspects of the aging process, such as epigenetic alterations, cellular senescence, and metabolic dysfunction.

[3]. Personalized interventions: Based on an individual's BA profile, personalized interventions can be developed to target specific aging mechanisms and optimize healthspan [11]. These interventions may include lifestyle modifications, such as diet and exercise, as well as pharmacological and regenerative therapies.

[4]. Longitudinal studies: To validate the efficacy of BA optimization strategies, longitudinal studies are needed to track changes in BA biomarkers and health outcomes over time [12]. These studies can provide valuable insights into the long-term effects of interventions and help refine personalized approaches to healthspan extension.



Fig. 2: Schematic representation of the potential applications of regenerative medicine, such as stem cell therapies and tissue engineering, in reversing the effects of biological aging

Observed Results

Several studies have demonstrated the potential of BA optimization strategies to extend healthspan and lifespan in animal models and humans:

[1]. Calorie restriction: Calorie restriction without malnutrition has been shown to extend lifespan and healthspan in various animal models [13]. In humans, calorie restriction has been associated with improvements in BA biomarkers, such as reduced inflammation and improved insulin sensitivity [14].

[2]. Exercise: Regular physical activity has been shown to attenuate age-related functional decline and reduce the risk of chronic diseases [15]. Exercise interventions have been associated with improvements in BA biomarkers, such as increased telomere length and reduced inflammation [16].
[3]. Pharmacological interventions: Several drugs, such as metformin and rapamycin, have shown promise in modulating aging pathways and extending healthspan in animal models [17]. In humans, metformin has been associated with reduced risk of age-related diseases and improved BA biomarkers [18].
[4]. Regenerative therapies: Stem cell therapies and tissue engineering approaches have the potential to regenerate aged or damaged tissues and extend healthspan [19]. In animal models, stem cell interventions have been shown to improve age-related functional decline and extend lifespan [20].

These observed results demonstrate the feasibility and potential of BA optimization strategies to promote healthy longevity. However, more research is needed to validate these findings in larger, more diverse human populations and to develop personalized approaches to BA optimization.

Use Cases

The optimization of BA has several potential use cases in healthcare and beyond:
[1]. Personalized medicine: BA assessment can be used to guide personalized interventions and treatment decisions, taking into account an individual's unique biological profile [21]. This approach can help optimize the effectiveness of interventions and minimize adverse effects.
[2]. Preventive healthcare: By identifying individuals with accelerated biological aging, BA assessment can facilitate early intervention and prevention of age-related diseases [22]. This can help reduce healthcare costs and improve quality of life in later years.
[3]. Clinical trial enrichment: BA biomarkers can be used to identify individuals at higher risk of age-related diseases or functional decline, allowing for more targeted recruitment in clinical trials [23]. This can help optimize the efficiency and effectiveness of trials for interventions aimed at extending healthspan.
[4]. Longevity research: BA assessment can be used to track the effectiveness of interventions aimed at slowing or reversing the aging process [24]. This can help accelerate the development of novel therapies and strategies for healthspan extension.
[5]. Wellness and performance optimization: BA assessment can be used to guide lifestyle interventions and track progress in healthy individuals seeking to optimize their health and performance [25]. This can have applications in fields such as sports, military, and space exploration.

Conclusion

The optimization of biological age represents a promising approach to extending healthspan and lifespan. By identifying and targeting key biomarkers of BA, we may be able to develop personalized interventions that slow or reverse the aging process, reducing the burden of age-related diseases and promoting healthy longevity.

However, several challenges need to be addressed to fully realize the potential of BA optimization. These include the standardization of BA biomarker panels, the development of validated interventions, and the need for large-scale longitudinal studies to assess the long-term effects of BA optimization strategies.

As the field of biological aging continues to evolve, it is crucial to adopt a multidisciplinary approach that integrates basic science, translational research, and clinical practice. By working together, researchers, healthcare providers, and policymakers can help unlock the potential of BA optimization to extend healthspan and improve quality of life for individuals and populations worldwide.

Acknowledgment

The authors would like to thank the participants in the user testing for their valuable feedback and contributions to this research.

References

[1]. López-Otín, C., Blasco, M. A., Partridge, L., Serrano, M., & Kroemer, G. (2013). The hallmarks of aging. Cell, 153(6), 1194-1217. https://doi.org/10.1016/j.cell.2013.05.039
[2]. Belsky, D. W., Caspi, A., Houts, R., Cohen, H. J., Corcoran, D. L., Danese, A., ... & Moffitt, T. E. (2015). Quantification of biological aging in young adults. Proceedings of the National Academy of Sciences, 112(30), E4104-E4110. https://doi.org/10.1073/pnas.1506264112

[3]. Levine, M. E. (2013). Modeling the rate of senescence: Can estimated biological age predict mortality more accurately than chronological age? Journals of Gerontology Series A: Biomedical Sciences and Medical Sciences, 68(6), 667-674. https://doi.org/10.1093/gerona/gls233
[4]. Jylhävä, J., Pedersen, N. L., & Hägg, S. (2017). Biological age predictors. EBioMedicine, 21, 29-36. https://doi.org/10.1016/j.ebiom.2017.03.046
[5]. Barzilai, N., Crandall, J. P., Kritchevsky, S. B., & Espeland, M. A. (2016). Metformin as a tool to target aging. Cell Metabolism, 23(6), 1060-1065. https://doi.org/10.1016/j.cmet.2016.05.011
[6]. Mitnitski, A. B., Mogilner, A. J., & Rockwood, K. (2001). Accumulation of deficits as a proxy measure of aging. The Scientific World Journal, 1, 323-336. https://doi.org/10.1100/tsw.2001.58
[7]. Ferrucci, L., Levine, M. E., Kuo, P. L., & Simonsick, E. M. (2018). Time and the metrics of aging. Circulation Research, 123(7), 740-744. https://doi.org/10.1161/CIRCRESAHA.118.312816
[8]. Kennedy, B. K., Berger, S. L., Brunet, A., Campisi, J., Cuervo, A. M., Epel, E. S., ... & Sierra, F. (2014). Geroscience: Linking aging to chronic disease. Cell, 159(4), 709-713. https://doi.org/10.1016/j.cell.2014.10.039
[9]. Horvath, S., & Raj, K. (2018). DNA methylation-based biomarkers and the epigenetic clock theory of ageing. Nature Reviews Genetics, 19(6), 371-384. https://doi.org/10.1038/s41576-018-0004-3
[10]. Ferrucci, L., Gonzalez-Freire, M., Fabbri, E., Simonsick, E., Tanaka, T., Moore, Z., ... & de Cabo, R. (2019). Measuring biological aging in humans: A quest. Aging Cell, 19(2), e13080. https://doi.org/10.1111/acel.13080
[11]. Moskalev, A., Chernyagina, E., Kudryavtseva, A., & Shaposhnikov, M. (2017). Geroprotectors: A unified concept and screening approaches. Aging and Disease, 8(5), 354-363. https://doi.org/10.14336/AD.2016.1022
[12]. Moffitt, T. E., Belsky, D. W., Danese, A., Poulton, R., & Caspi, A. (2017). The longitudinal study of aging in human young adults:Knowledge gaps and research agenda. The Journals of Gerontology: Series A, 72(2), 210-215. https://doi.org/10.1093/gerona/glw191
[13]. Fontana, L., & Partridge, L. (2015). Promoting health and longevity through diet: From model organisms to humans. Cell, 161(1), 106-118. https://doi.org/10.1016/j.cell.2015.02.020
[14]. Most, J., Tosti, V., Redman, L. M., & Fontana, L. (2017). Calorie restriction in humans: An update. Ageing Research Reviews, 39, 36-45. https://doi.org/10.1016/j.arr.2016.08.005
[15]. Garatachea, N., Pareja-Galeano, H., Sanchis-Gomar, F., Santos-Lozano, A., Fiuza-Luces, C., Morán, M., ... & Lucia, A. (2015). Exercise attenuates the major hallmarks of aging. Rejuvenation Research, 18(1), 57-89. https://doi.org/10.1089/rej.2014.1623
[16]. Valenzuela, P. L., Castillo-García, A., Morales, J. S., de la Villa, P., Hampel, H., Emanuele, E., ... & Lucia, A. (2019). Exercise benefits on Alzheimer's disease: State-of-the-art. Ageing Research Reviews, 52, 120-130. https://doi.org/10.1016/j.arr.2019.04.008
[17]. Blagosklonny, M. V. (2017). From rapalogs to anti-aging formula. Oncotarget, 8(22), 35492-35507. https://doi.org/10.18632/oncotarget.18033
[18]. Barzilai, N., Crandall, J. P., Kritchevsky, S. B., & Espeland, M. A. (2016). Metformin as a tool to target aging. Cell Metabolism, 23(6), 1060-1065. https://doi.org/10.1016/j.cmet.2016.05.011
[19]. Mahla, R. S. (2016). Stem cells applications in regenerative medicine and disease therapeutics. International Journal of Cell Biology, 2016, 6940283. https://doi.org/10.1155/2016/6940283
[20]. Zhang, Y., Unnikrishnan, A., Deepa, S. S., Liu, Y., Li, Y., Ikeno, Y., ... & Van Remmen, H. (2017). A new role for oxidative stress in aging: The accelerated aging phenotype in Sod1-/- mice is correlated to increased cellular senescence. Redox Biology, 11, 30-37. https://doi.org/10.1016/j.redox.2016.10.014
[21]. Ledford, H. (2015). Drugs that lengthen life span are set to rewrite medicine. Nature, 522(7556), 267-269. https://doi.org/10.1038/522267a
[22]. Moskalev, A. (2019). The challenges of estimating biological age. eLife, 8, e54969. https://doi.org/10.7554/eLife.54969
[23]. Justice, J. N., Ferrucci, L., Newman, A. B., Aroda, V. R., Bahnson, J. L., Divers, J., ... & Kritchevsky, S. B. (2018). A framework for selection of blood-based biomarkers for geroscience-guided clinical trials: Report from the TAME Biomarkers Workgroup. GeroScience, 40(5-6), 419-436. https://doi.org/10.1007/s11357-018-0042-y
[24]. Sierra, F. (2016). The emergence of geroscience as an interdisciplinary approach to the enhancement of health span and life span. Cold Spring Harbor Perspectives in Medicine, 6(4), a025163. https://doi.org/10.1101/cshperspect.a025163
[25]. Gao, X., Zhang, Y., Saum, K. U., Schöttker, B., & Brenner, H. (2019). Accelerated aging in midlife: Evidence from a longitudinal cohort study. The Journals of Gerontology: Series A, 74(2), 217-225. https://doi.org/10.1093/gerona/gly